Theophylline and 1-methyl-3-isobutylxanthine (MIX), compounds that block eicosanoid formation and modulate phospholipase A2 activity, inhibited in a dose-dependent manner the formation of both leukotriene B4 (LTB,) and platelet-activating factor (PAF) by human polymorphonuclear leucocytes (PMN) in response to ionophore A23187. Theophylline and MIX lacked any inhibitory effect on acetyl-CoA: lyso-PAF acetyltransferase activity, which is the ratelimiting step for PAF biosynthesis in PMN. The effect of theophylline and MIX on PAF formation could be reversed by incubating the cells in the presence of 1-10 /LM exogenous lyso-PAF. Incubation of PMN homogenates in the presence of unsaturated non-esterified fatty acids resulted in dose-dependent inhibition of the acetyltransferase. This effect was linked to the presence of a free carboxyl group, since both arachidonic acid methyl ester and palmitoyl-arachidonoyl phosphatidylcholine lacked inhibitory activity. This inhibitory effect was also dependent on the number of double bonds, since arachidonic acid (C20 :4) and eicosapentaenoic acid (C20 :5) displayed maximal effect. Kinetic analysis showed that the effect of arachidonic acid was consistent with competitive inhibition, with a K1 value of about 19 /IM. Oxidative metabolites of arachidonic acid showed a lesser inhibitory effect with the following order of potency: arachidonic acid > 15-HETE (15-hydroxy-6,8,11,14-eicosatetraenoic acid) > LTB4> 5-HETE (5-hydroxy-6,8,11,14-eicosatetraenoic acid) > lipoxin A4. Examination of enzymes involved in CoA-dependent acylation revealed a low activity of both arachidonoyl-CoA synthetase and arachidonoyl-CoA: lyso-PAF arachidonoyltransferase. These data indicate a strong influence on PAF biosynthesis of the products of the phospholipase A2 reaction, with lyso-PAF disposal being a critical event for PAF formation, and unsaturated fatty acids acting as feed-back inhibitors. The conversion of arachidonic acid via oxidative metabolism into less active inhibitors of acetyl-CoA: lyso-PAF acetyltransferase seems to be an additional mechanism of modulation of this enzyme activity, linked to the function of lipoxygenases. Finally, the enzyme activities involved in arachidonoyl-CoA-dependent acylation of lyso-PAF show a low efficiency in capturing arachidonic acid.
INTRODUCTION
Activation of polymorphonuclear leucocytes (PMN) on interaction with secretagogues initiates the biosynthesis of eicosanoids, especially leukotriene B4 (LTB4) in intact cells [1] , and platelet-activating factor (PAF) [2] [3] [4] . These lipid mediators show a number of similarities, e.g. biosynthesis from common precursors, induction or/and modulation of their biosynthesis by each other, and overlapping spectra of biological activities.
The compound I-alkyl-2-arachidonoyl-sn-3-glycerophosphocholine is a common precursor for the biosynthesis of eicosanoids and of PAF in PMN [5, 6] . Accordingly, a phospholipase A2 (EC 3.1.1.4) acting on this compound [7] produces both arachidonic acid to be used for the synthesis of eicosanoids, and lyso-PAF to be utilized in the remodelling pathway for the synthesis of PAF by an acetyl-CoA: lyso-PAF acetyltransferase (1 -alkylglycerophosphocholine acetyltransferase; EC 2.3.1.67). Current views stress the role of phospholipase A2 and 5-lipoxygenase activities [8] [9] [10] as rate-limiting for the synthesis of LTB4, whereas acetylCoA: lyso-PAF acetyltransferase [11] seems to be limiting step in the formation of PAF, since only those secretagogues that activate this enzyme via a phosphorylation-dephosphorylation mechanism initiate the biosynthesis of PAF in PMN, macrophages and exocrine secretory glands [12] [13] [14] [15] [16] [17] [18] [19] .
Moreover, some 5-lipoxygenase products have been reported to modulate PAF biosynthesis by acting at the phospholipase A2 level [20, 21] , and unsaturated non-esterified fatty acids are either reversible and non-competitive inhibitors of phospholipase A2 by a mechanism that is best explained by an interaction at an allosteric site(s) [22] , or reversible and competitive inhibitors [23] . A study by Ramesha & Pickett [24] has shown a significant diminution of the generation of both PAF and LTB4 in PMN from rats depleted of arachidonic acid and the almost complete recovery of the generation of these mediators on addition of exogenous arachidonic acid. In another study, the production of PAF by human monocytes was enhanced by exogenous arachidonic acid and diminished by eicosapentaenoic acid [25] , a prominent component of diets enriched with fish oil, the metabolism of which is associated with inhibition of LTB4 generation from membrane-derived arachidonic acid and with conversion to chemotactically inactive 5-hydroxyeicosapentanoic acid or attenuated LTB5 [26] . So far, two explanations for this effect of arachidonic acid have been provided: either (1) a 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine precursor is required for PAF biosynthesis [24] or (2) lipoxygenase products of arachidonic acid modulate PAF biosynthesis by enhancing the expression of phospholipase A2 [20, 21] . This study is intended to characterize some factors that can influence PAF formation Vol. 268
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* To whom correspondence and reprint requests should be addressed. through the remodelling pathway acting at the acetyl-CoA: lyso-PAF acetyltransferase level, and that are independent of the already characterized mechanism of modulation of this enzyme activity linked to a phosphorylation-dephosphorylation reaction.
In this paper we report the following: (1) Assay of lyso-PAF:acetyl-CoA acetyltransferase
The assay was performed as described in [12] . For this purpose, PMN at a concentration of 107 cells/ml in a Tris/HCI-buffered medium, pH 7.4, were sonicated for 15 s in a Branson B-12 sonifier equipped with microtip at position 3. The assay was carried out in the presence of 20 4uM-lyso-PAF, 0.5 ,uCi of [3H]acetyl-CoA and 100 UM unlabelled acetyl-CoA. The enzyme reaction was carried out for 15 min at 37°C and stopped by the addition of 3.7 ml of chloroform/methanol (1:2, v/v) for lipid extraction. The product extracted into the chloroform layer was separated by t.l.c. on silica-gel plates using as developer the system propionic acid/propanol/chloroform/water (2:2: 1: 1, by vol.). The areas of the plates coincident with the RF of a standard of synthetic PAF were scraped off and counted for radioactivity.
Assay of acyl-CoA: lysophosphatide acyltransferase (EC 2.3.1.23)
The assay was carried out in homogenates of PMN as described by Lands et al. [34] . The medium contained either oleoyl-or arachidonoyl-CoA, 0.2 1sCi of [1-14C] acyl-CoA and 20 ,uM-lyso-PAF in 1 ml of 0.1 M-Tris/HCl-buffered medium, pH 7.4. The reaction was carried out and stopped as described for acetylCoA: lyso-PAF acetyltransferase, except that the phosphatidylcholine zone was scraped for scintillation counting. Data before the addition of 10 /IM-ionophore A23187 (-) or control solutions (Ol). After 10 min of incubation supernatants were taken for extraction and LTB4 assay as described in the Materials and methods section. Data represent means+ S.D. of four (THE) or six (MIX) independent experiments done in duplicate. Significant differences from controls are indicated: * P < 0.05; ** P < 0.01.
bromophenacyl bromide, an active-site-directed inhibitor, which has been used to characterize phospholipases. However, pbromophenacyl bromide was also found to inhibit acetyl-CoA: lyso-PAF acetyltransferase activity in PMN homogenates in the range 1-100 /LM (Table 1) , i.e. similar to reports on phospholipase A2 [35, 36] and rat spleen acetyltransferase [11] . This finding discouraged the use of this compound and prompted us to utilize methylxanthines, which have a rapid inhibitory effect on phospholipase A2 activity in intact cells [8, 37] that seems to be independent from their effect on cyclic AMP-dependent phosphodiesterase [38, 39] and which also lack a significant direct effect on acetyl-CoA: lyso-PAF acetyltransferase (see below). In addition, in a previous report we have observed that MIX is a potent inhibitor of the release of arachidonic acid from human PMN [40] . The label was lost after phospholipase A, treatment of some selected samples. which indicated that the label was incorporated at the s,i-2 position and had not been added on to the alkyl chain. When PMN were preincubated in the presence of either theophylline or MIX, a dose-dependent inhibition of label incorporation was observed (Fig. 3) . The (Figs. 4a and 4h ). This is in keeping with the hypothesis of a possible inhibitory effect of methylxanthines at the phospholipase A, level.
Effect of methylxanthines on acetyl-CoA: lyso-PAF acetyltransferase activity Preincubation of PMN in the presence of I 1iM-MIX produced no significant effect on acetyl-CoA:lyso-PAF acetyltransferase activity, which increased from 122 + 24 to 136 + 21 pmol/min per 107 PMN (n= 5). Similar findings were observed when PMN were preincubated with I mM-theophylline, which also caused an increase in acetyl-CoA: lyso-PAF acetyltransferase activity to 148+15 pmol/min per 10, PMN (n = 4). Similar non-inhibitory effects were also observed when methylxanthines were added to PMN stimulated with ionophore A23187 (Fig. 5) (Fig. 7a) . When the assay was carried out with [1-14C]oleoyl-CoA (Fig. 7b) , the enzyme activity was 470 pmol/min per 107 PMN, which was similar to the activity in indicates that other pathways should be responsible for the enrichment of alkyl-ether lipids in arachidonate molecular species, as had been shown in rabbit alveolar macrophages [44] and platelets [46] . A further consequence of these findings is that changes in the rate of reacylation of lyso-PAF seem to play a limited role in the modulation of PAF formation.
Arachidonoyl-CoA synthetase activity in platelets and PMN Experiments were carried out by processing in parallel platelet and PMN membrane fractions obtained from the same donor; for this purpose, blood was always centrifuged at low speed to remove platelet-rich plasma before PMN isolation. Under these conditions, there was a recognized source of enzyme in each experiment and the possible contribution by contaminating platelets to the activity assayed in PMN membranes could be assessed. As shown in Table 3 , PMN contained much less enzyme activity than platelets, even when the membrane fraction had been obtained from cells stimulated previously with ionophore A23 187, which has been shown to enhance this enzyme activity in human platelets [47] .
DISCUSSION
The data herein presented indicate an important role for the products of the phospholipase A2 reaction in the modulation of PAF biosynthesis. A consequence of these findings with potential therapeutic value is that pharmacological agents acting at this enzyme step can influence formation of both PAF and LTB4. The first pharmacological tool we used to block phospholipase A2 was p-bromophenacyl bromide, an active-site-directed inhibitor (although this concept has been challenged by Kyger & Franson [48] who found that p-bromophenacyl bromide can also react with thiol groups), but this was found not to be suitable.
Previous studies have shown the inhibition of the generation of LTB4 [49, 50] and PAF [51] in response to both complementcoated zymosan particles and calcium ionophore A23187 by increasing intracellular levels of cyclic AMP with pharmacological tools, methylxanthines being the most effective agents. However, few studies are available concerning the enzyme on which cyclic AMP and methylxanthines seem to exert this inhibitory role. Moreover, some discrepancies are raised by previous findings on the inhibition of PAF generation by methylxanthines and the description of the activation of acetylCoA: lyso-PAF acetyltransferase activity by the catalytic subunit ofcyclic AMP-dependent protein kinase in rat spleen microsomes [17] , PMN homogenates [19] and guinea-pig parotid gland microsomes [151. The present results indicate a dual effect of methylxanthines on PAF formation. On the one hand, MIX and Vol. 268 theophylline block the generation of both PAF and LTB4, and this agrees with an inhibitory effect at the phospholipase A2 level. On the other hand, they do not inhibit (and even slightly enhance) the passage of acetyl-CoA :Iyso-PAF acetyltransferase from a low-activity form to a high-activity form, even though the incorporation of [14C]acetate in [14C]PAF is diminished. Since the effect of both theophylline and MIX could be partially reversed by the addition of lyso-PAF to the PMN, the most relevant inhibitory effect of these compounds on PAF biosynthesis can be related to an effect on lyso-PAF disposal.
Both phospholipase A2 and acetyl-CoA: Iyso-PAF acetyltransferase are inhibited by unsaturated fatty acids by a competitive mechanism. According to this finding, non-esterified unsaturated fatty acids seem to play a modulatory role in PAF biosynthesis which is linked to phospholipase A2 activity, since their intracellular level depends on the deacylation/reacylation rate, and detectable levels of free arachidonic acid are only found after phospholipase activation in many cell types, e.g. human platelets [52] . Interestingly, the effect of arachidonic acid herein described is observed at concentrations below its critical micellar concentration. Those concentrations are equal to or lower than the concentrations required to display other pharmacological properties of unsaturated fatty acids, e.g. stimulation of glycolysis in intact lymphocytes [53] and inhibition of 5-lipoxygenase in alveolar macrophages [54] . The structure-activity study indicates a more potent effect of fatty acids containing double bonds, and the need for a free carboxylic group for the expression of the effect. This would suggest that the action of arachidonic acid may in turn be modulated by either oxidation or reacylation via formation of an arachidonoyl-CoA intermediate [30] . The comparable effects of unsaturated fatty acids on spleen microsomes and A23187-stimulated PMN indicate that the effect of arachidonic acid cannot be related to oxidative metabolism. This agrees with recent reports on 5-lipoxygenase, a soluble hydrophobic enzyme that rapidly loses activity and undergoes translocation to the membrane [10] when it catalyses ionophore-induced arachidonic acid metabolism. The low conversion rate of arachidonate into 5-lipoxygenase-produced metabolites found in our experiments, even in the resting homogenates, can be explained by the requirements of this enzyme for multiple stimulatory factors including ATP and hydroperoxy derivatives of polyenoic fatty acids [9, 10] .
Another factor that could influence PAF formation is the activity of the enzymes involved in the CoA-dependent reacylation of lyso-PAF. We have detected a low arachidonoylCoA synthetase activity in human PMN, which is at variance with reports on platelets [30, 47] , and a preference for oleoylCoA as a substrate of acyl-CoA: lyso-phosphatide acyltransferase. This activity was not influenced by previous activation of the PMN, whereas some differences in enzyme activity between resting and ionophore-A23187-activated PMN were detected with arachidonoyl-CoA as substrate. This suggests the existence of two enzymes with different affinities for the two substrates, and indicates that accumulation of arachidonoyl species in the alkyl subclass of choline-containing phosphoacylglycerols cannot be explained by an arachidonoyl-CoA:
lysophosphatide acyltransferase reaction, but most probably by a CoA-independent transacylation such as that described in rabbit alveolar macrophages [44] . In summary, our data enlarge the list of factors implicated in the modulation of acetyl-CoA: lyso-PAF acetyltransferase. 
